Drug Trial Radar · NCT03531905
Bempedoic Acid + Ezetimibe Fixed-Dose Combination (FDC) Study in Patients With Type 2 Diabetes and Elevated LDL-C
Last checked: Nov 19, 2026Latest source record: Apr 9, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
242
Actual
Start
May 9, 2018
Primary completion
Jun 18, 2019
Study completion Jun 18, 2019
Sponsor
- Lead sponsor
- Esperion Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 22, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Factorial
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
12 week study to assess the LDL-C lowering efficacy, other lipid and glycemic measures, and safety of bempedoic acid/ezetimibe FDC compared to ezetimibe and placebo in patients with type 2 diabetes (T2D) and elevated LDL-C
Conditions
- Diabetes
- Diabetes Mellitus, Type 2
- Cholesterolemia
Interventions
Bempedoic acid + Ezetimibe FDC Oral TabletDrug
Experimental therapy of bempedoic acid 180 mg + ezetimibe 10 mg FDC tablet
Ezetimibe 10 mg Oral TabletDrug
Ezetimibe 10 mg tablet, overencapsulated for blinding purposes
Placebo Oral TabletDrug
Placebo tablet, matched for the FDC product for blinding purposes
Placebo oral capsuleDrug
Placebo over-encapsulated for blinding purposes
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change From Baseline to Week 12/End of Study (EOS) in Low-density Lipoprotein Cholesterol (LDL-C)Time frame: Baseline; Week 12
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Clinical Trials Research
Lincoln, California
FInlay Medical Research
Miami, Florida
L-MARC Research Center
Louisville, Kentucky
Hampton Roads Center for Clinical Research
Suffolk, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.